Metagenomi Therapeutics, Inc. (MGX)
| Market Cap | 30.83M -75.5% |
| Revenue (ttm) | 13.56M -59.8% |
| Net Income | -93.46M |
| EPS | -2.49 |
| Shares Out | 37.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,263 |
| Open | 0.8108 |
| Previous Close | 0.8288 |
| Day's Range | 0.8019 - 0.8360 |
| 52-Week Range | 0.7690 - 3.2100 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+757.0%) |
| Est. Earnings | Nov 10, 2026 |
About MGX
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other... [Read more]
Financial Performance
In 2025, Metagenomi Therapeutics's revenue was $25.21 million, a decrease of -51.79% compared to the previous year's $52.30 million. Losses were -$87.87 million, 12.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 757.00% from the latest price.
News
Metagenomi Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
MGX-001 showed durable, dose-dependent factor VIII activity in NHPs, supporting a Phase I/II study planned for next year. EPI-321 interim six-month data showed muscle-volume and strength gains, alongside a decline in the DUCZ biomarker.
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to cre...
Metagenomi Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
MGX-001 for Hemophilia A is advancing toward IND submission in Q4, with clinical entry targeted for 2027. Preclinical data show durable, dose-dependent Factor VIII expression and a favorable safety profile. The platform supports pipeline expansion and strong investigator and patient interest.
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
EMERYVILLE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to cr...
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby yo...
Metagenomi price target lowered to $7 from $9 at Wells Fargo
Wells Fargo lowered the firm’s price target on Metagenomi (MGX) to $7 from $9 and keeps an Overweight rating on the shares following quarterly results. The firm notes MGX-001 remains…
Metagenomi Therapeutics Quarterly report: Q2 2026
Metagenomi Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Metagenomi Therapeutics Earnings release: Q2 2026
Metagenomi Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic condition...
Metagenomi transferred with a Buy at Chardan
Chardan took over coverage of Metagenomi (MGX) Therapeutics with an unchanged Buy rating and new price target at $5, citing the potential of its lead asset MGX-001 as a one-time…
Metagenomi Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, approved the election of two directors, and ratified the appointment of PricewaterhouseCoopers as auditor. No additional director nominations or relevant stockholder questions were received.
Metagenomi Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing MGX-001, a proprietary gene-editing therapy for hemophilia A, with IND submission planned for Q4 and clinical entry in 2027. Preclinical data show durable, safe factor VIII expression, and strong community engagement supports the approach. Cash runway extends through Q4 2027.
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference
EMERYVILLE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to crea...
Metagenomi price target lowered to $9 from $12 at Wells Fargo
Wells Fargo lowered the firm’s price target on Metagenomi (MGX) to $9 from $12 and keeps an Overweight rating on the shares. Following the company’s Q1 update, the firm notes…
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology...
Metagenomi Therapeutics Earnings release: Q1 2026
Metagenomi Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Metagenomi Therapeutics Quarterly report: Q1 2026
Metagenomi Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Metagenomi Therapeutics Proxy statement: Proxy filing
Metagenomi Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Metagenomi Therapeutics Proxy statement: Proxy filing
Metagenomi Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Metagenomi announces publication on MG119-28
Metagenomi (MGX) Therapeutics announced a publication in Nature Structural & Molecular Biology highlighting the discovery and detailed characterization of MG119-28, a compact CRISPR nuclease with supe...
Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing Efficiency
Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investig...
Metagenomi Therapeutics Annual report: Q4 2025
Metagenomi Therapeutics has published its Q4 2025 annual report on March 5, 2026.
Metagenomi Therapeutics Earnings release: Q4 2025
Metagenomi Therapeutics released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Metagenomi Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted the advancement of MGX-001 as a potential one-time curative treatment for hemophilia A, with IND submission targeted for Q4 and a strong focus on safety, durability, and market readiness. Strategic partnerships and capital allocation support a robust pipeline and financial runway.